. 2018 Oct 31;9(23):4510–4520. doi: 10.7150/jca.27611

Table 3.

Meta-analyses of grade 3 and above adverse events for comparisons 1 and 2

Adverse events	N of studies	N of pts in mAb group	N of pts in control group	RR (95% CI)	P-value^a	Heterogeneity
Adverse events	N of studies	N of pts in mAb group	N of pts in control group	RR (95% CI)	P-value^a	I²	P-value^a
Comparison 1: RT/CRT + anti-EGFR mAbs versus RT/CRT alone
Leukopenia	7	565	1147	0.99 (0.83-1.19)	0.95	11%	0.34
Thrombocytopenia	5	438	1013	1.01 (0.53-1.95)	0.97	13%	0.33
Anemia	5	477	1049	1.21 (0.68-2.15)	0.52	9%	0.35
Nausea/vomiting	7	565	1147	0.95 (0.58-1.56)	0.84	46%	0.09
Liver dysfunction	3	294	869	1.18 (0.55-2.54)	0.68	0%	0.66
Renal impairment	1	189	689	0.87 (0.33-2.27)	0.77	NA	NA
Radiodermatitis	5	163	304	1.04 (0.81-1.35)	0.74	0%	0.68
Skin rash	4	358	943	4.08 (1.59-10.47)	0.003	70%	0.02
Mucositis	7	565	1152	1.84 (1.10-3.10)	0.02	89%	< 0.001
Weight loss	2	264	839	1.51 (0.95- 2.39)	0.08	0%	0.62
Comparison 2: RT + Concurrent Anti-EGFR mAbs Versus CCRT
Leukopenia	3	251	680	0.23 (0.10-0.53)	< 0.001	51%	0.13
Thrombocytopenia	4	279	712	0.27 (0.11-0.62)	0.002	0%	0.59
Anemia	3	227	660	0.09 (0.03-0.33)	< 0.001	0%	0.92
Nausea/vomiting	4	279	712	0.10 (0.05-0.18)	< 0.001	10%	0.34
Liver dysfunction	3	227	660	1.41(0.10-20.76)	0.80	60%	0.08
Renal impairment	3	227	660	0.20 (0.05-0.79)	0.02	48%	0.15
Radiodermatitis	1	52	52	2.00 (0.19-21.38)	0.57	NA	NA
Skin rash	5	300	735	4.09 (1.21-13.87)	0.02	63%	0.03
Mucositis	5	300	735	1.28 (0.97-1.68)	0.08	61%	0.04
Weight loss	3	251	680	0.96 (0.64- 1.45)	0.84	12%	0.32

Abbreviations: N = number; pts = patients; anti-EGFR mAb = anti-epidermal growth factor receptor monoclonal antibody; RT = radiotherapy; CRT = chemoradiotherapy; CCRT = concurrent chemoradiotherapy; RR = risk ratio; CI = confidence interval; NA = not applicable. ^a Statistically significant results are shown in bold.